Oscar, 52 — twenty-five years of Grave's, and the amalgam fillings that started it.

Twenty-five years in.

Oscar, fifty-two, came to us from Oslo carrying a diagnosis older than most of our patients' relationships with their own GPs. Grave's disease, twenty-five years standing. By the time he reached Clinic82 he had lived more than half of his adult life inside a chronic autoimmune thyroid condition, on and off medication, managing rather than resolving.

His presentation was the accumulated weight of a long illness rather than an acute flare: irritability, anxiety, emotional instability, vision problems, and a fatigue that arrived disproportionately after physical activity. He was on neomercazole 5mg twice daily to suppress thyroid hormone production, and levothyroxine 125mcg once daily to replace what the suppression — and the disease itself — had taken from him. Two medications pulling in opposite directions, which is not unusual in long-standing Grave's management, but it is a sign of a system being held rather than resolved.

What made this case distinctive was not the diagnosis. It was the origin story Oscar told us himself, unprompted, and the question of whether it deserved to be taken seriously.

What we measured.

A twenty-five-year history does not get re-explained by a single test. Our working approach with long-standing Grave's is to re-establish the full picture rather than assume the original workup, from a quarter-century ago, still describes the terrain. That meant building the panel from the ground up.

Five domains, run in parallel, because in a case this long-standing, no single result was likely to explain the whole picture on its own.

TRAb at eleven.

The thyroid ultrasound showed an enlarged gland with slight tissue inhomogeneity, a few cysts under 3mm, a few nodules under 3mm, and normal adjacent salivary glands with no enlarged lymph nodes — a picture consistent with long-standing autoimmune thyroid activity rather than an acute or malignant process.

The antibody result was the number that mattered most. TRAb came back at 11, against a normal reference of under 1.8 — more than six times the upper limit, and unambiguous confirmation that the autoimmune driver of Oscar's Grave's disease was still active after twenty-five years, not merely a historical diagnosis being managed by medication alone.

The heavy-metal urine panel returned a pattern worth taking seriously. Excretion of mercury, arsenic, barium, rubidium, and tin was elevated; lead, antimony, caesium, and nickel showed moderate increases. The separate sensitivity panel added nuance: mild intolerance to aluminium and silver, but no reactivity to lead, mercury, organic mercury, nickel, or cadmium — a distinction between body burden and immune sensitisation that we manage as clinically separate questions.

Viral serology showed IgG antibodies to measles, Epstein-Barr virus, and cytomegalovirus — evidence of past exposure, common in the general population, but relevant in the context of autoimmune thyroid disease where viral molecular mimicry is an active area of clinical interest.

The stool panel showed increased IgA, an elevated overall microbial load, Blastocystis spp. confirmed by PCR, and culture growth of Klebsiella oxytoca and Citrobacter freundii. A gut terrain under strain, in other words, sitting alongside an active autoimmune thyroid process.

Four positive domains. None of them, individually, explains twenty-five years of Grave's disease. Together, they gave us a working map of where to intervene.

Two weeks in Cyprus.

Oscar's plan combined an intensive two-week in-clinic phase in Cyprus with a continued protocol at home. The in-clinic phase was built to address the heavy-metal body burden directly while supporting the systems that would need to carry that load out of the body.

• DMPS chelation, intravenous — a chelating agent selected for its affinity for mercury and related metals, administered under supervision given Oscar's specific excretion pattern.
• Magnetic field therapy — adjunctive supportive therapy used alongside detoxification protocols at the clinic.
• Intestinal hydrotherapy — addressing the gut terrain findings directly, in parallel with the elevated microbial load and organisms identified on stool testing.
• Plaque injection therapy — part of the broader supportive protocol used during the in-clinic phase.
• Phosphatidylcholine infusions — supporting cellular membrane health during the detoxification period.

Medication — neomercazole and levothyroxine — was not withdrawn. It was monitored and titrated downward only as thyroid function and antibody trends allowed, which is the sequence we consider non-negotiable in a case with a twenty-five-year medication history.

A patient's own account.

Oscar was clear, and consistent, about when his illness began. In his own words, given during intake:

"The problems began when I had my amalgam fillings removed. Along with irritability, anxiety and emotional instability, I started experiencing vision problems. I now easily tire and exhaust myself with no worries, especially after participating in sports activities." — Oscar

We want to be precise about what this account is, and what it is not. It is patient-reported chronology — a memory of temporal association between a dental procedure and the onset of symptoms that were later diagnosed as Grave's disease. It is not, on its own, proof of causation, and twenty-five years of recall is subject to the same limitations as any retrospective history.

What makes it worth taking seriously is biological plausibility, not certainty. Amalgam fillings are roughly 50% elemental mercury by weight, and removal — particularly without vapour extraction, a rubber dam, or cooling water spray — can produce a measurable spike in mercury vapour inhalation and short-term systemic mercury absorption. Oscar's heavy-metal panel, a quarter-century later, still showed elevated mercury excretion alongside several other elements, which is consistent with a chronic body burden but does not by itself confirm the fillings as the originating event; a lifetime of other environmental exposures could contribute to the same pattern.

There is a published literature associating mercury exposure with disruption of immune tolerance and, in some populations, with markers of thyroid autoimmunity — but this is an association observed across studies, not a demonstrated mechanism proven in any individual patient, and Grave's disease has multiple recognised triggers including genetic predisposition, smoking, stress, and other infections entirely independent of metal exposure. We addressed Oscar's account as a plausible contributing thread worth investigating clinically — which is why heavy metals were part of his panel at all — rather than as an established fact driving the treatment plan on its own.

The honest retrospective.

Results in a case like this are genuinely encouraging, but a twenty-five-year condition does not offer a clean before-and-after, and we want to be candid about where the plan could have been sequenced better.

• Staging the chelation more conservatively. DMPS chelation is effective, but in a patient with this excretion profile across five or more elements, we would today favour a more gradual staging protocol, with closer interim monitoring of mineral status, rather than a single intensive two-week push.
• A parallel mineral repletion protocol. Chelating agents do not distinguish perfectly between toxic and essential minerals. Pairing the DMPS course more deliberately with repletion of zinc, magnesium, and other trace elements likely lost alongside the targeted metals would have been a more complete approach.
• Setting expectations around pace. Autoimmune retreat is not linear. A patient with a twenty-five-year history should be told, clearly and early, that antibody normalisation — if it happens at all — happens in a stepwise and sometimes uneven pattern, not a straight line to a target number.

None of this changes what we observed. It changes how carefully we would sequence a similar case next time.

Reduced burden, not cure.

Two weeks after the in-clinic phase, Oscar's medication was reduced by 50% from baseline. Three further months of the home protocol brought that reduction to 75% of the original dose. Ongoing monitoring has shown his thyroid function tests returning to within the normal range, and by July 2022 his TRAb had fallen from 11 to 3.7 — a substantial move toward the normal threshold of under 1.8, though not yet within it.

We are deliberate about the language we use here. Oscar's autoimmunity was not cured. What changed, measurably, is that his medication burden fell substantially, his thyroid function tests returned to the normal range under monitoring, and his antibody titre moved from clearly pathological toward — but not yet into — the normal reference band. Grave's disease of twenty-five years' standing does not resolve on a single protocol, and we do not present this case as if it did.

What we do think this case demonstrates is the value of re-investigating a long-standing diagnosis rather than simply continuing to manage it. A patient's own account of when his illness began pointed us toward a heavy-metal panel that returned a genuinely abnormal result; that result, addressed carefully, appears to have been one contributing factor among several in a meaningful clinical improvement. Ongoing monitoring continues.